Quality of life should be the primary outcome for disease modifying therapy trials in MS-No
Mult Scler
.
2023 Aug;29(9):1066-1067.
doi: 10.1177/13524585231182708.
Epub 2023 Jul 25.
Authors
Emm Strijbis
1
,
M W Koch
2
,
B A de Jong
1
Affiliations
1
Department of Neurology, MS Center Amsterdam, Amsterdam UMC, Amsterdam, the Netherlands.
2
Department of Community Health Sciences, University of Calgary, Calgary, AB, Canada.
PMID:
37489564
PMCID:
PMC10413779
DOI:
10.1177/13524585231182708
No abstract available
MeSH terms
Humans
Immunosuppressive Agents
Multiple Sclerosis* / drug therapy
Multiple Sclerosis, Relapsing-Remitting*
Quality of Life
Substances
Immunosuppressive Agents